| Year |
Citation |
Score |
| 2024 |
Kim IK, Diamond MS, Yuan S, Kemp SB, Kahn BM, Li Q, Lin JH, Li J, Norgard RJ, Thomas SK, Merolle M, Katsuda T, Tobias JW, Baslan T, Politi K, ... Vonderheide RH, et al. Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. Nature Communications. 15: 1532. PMID 38378697 DOI: 10.1038/s41467-024-46048-7 |
0.376 |
|
| 2023 |
Blise KE, Sivagnanam S, Betts CB, Betre K, Kirchberger N, Tate B, Furth EE, Dias Costa A, Nowak JA, Wolpin BM, Vonderheide RH, Goecks J, Coussens LM, Byrne KT. Machine learning links T cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer. Biorxiv : the Preprint Server For Biology. PMID 37961410 DOI: 10.1101/2023.10.20.563335 |
0.366 |
|
| 2023 |
Cheng NC, Vonderheide RH. Immune vulnerabilities of mutant KRAS in pancreatic cancer. Trends in Cancer. PMID 37524642 DOI: 10.1016/j.trecan.2023.07.004 |
0.375 |
|
| 2023 |
Kim IK, Diamond M, Yuan S, Kemp S, Li Q, Lin J, Li J, Norgard R, Thomas S, Merolle M, Katsuda T, Tobias J, Politi K, Vonderheide R, Stanger B. Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy. Research Square. PMID 37398248 DOI: 10.21203/rs.3.rs-2960521/v1 |
0.428 |
|
| 2023 |
Kim R, Taylor D, Vonderheide RH, Gabrilovich DI. Ferroptosis of immune cells in the tumor microenvironment. Trends in Pharmacological Sciences. PMID 37380530 DOI: 10.1016/j.tips.2023.06.005 |
0.438 |
|
| 2023 |
Schratz KE, Flasch DA, Atik CC, Cosner ZL, Blackford AL, Yang W, Gable DL, Vellanki PJ, Xiang Z, Gaysinskaya V, Vonderheide RH, Rooper LM, Zhang J, Armanios M. T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers. Cancer Cell. 41: 807-817.e6. PMID 37037617 DOI: 10.1016/j.ccell.2023.03.005 |
0.327 |
|
| 2022 |
Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB, Joshi N, Yuan S, Smith M, Vostrejs WP, Perez-Vale KZ, ... ... Vonderheide RH, et al. Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discovery. PMID 36472553 DOI: 10.1158/2159-8290.CD-22-1066 |
0.39 |
|
| 2022 |
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, ... ... Vonderheide RH, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine. PMID 35662283 DOI: 10.1038/s41591-022-01829-9 |
0.375 |
|
| 2021 |
Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K, Scholler J, Posey AD, O'Hara MH, Smole A, Powell DJ, ... ... Vonderheide RH, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications. 12: 4365. PMID 34272369 DOI: 10.1038/s41467-021-24562-2 |
0.38 |
|
| 2021 |
Diamond MS, Lin JH, Vonderheide RH. Site-dependent immune escape of highly antigenic tumors without immunoediting. Cancer Immunology Research. PMID 34145076 DOI: 10.1158/2326-6066.CIR-20-0785 |
0.513 |
|
| 2021 |
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb CW, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, ... ... Vonderheide RH, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34112709 DOI: 10.1158/1078-0432.CCR-21-1047 |
0.352 |
|
| 2021 |
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, ... ... Vonderheide RH, et al. CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine. PMID 34017137 DOI: 10.1038/s41591-021-01386-7 |
0.366 |
|
| 2021 |
Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Vayrynen SA, Clancy TE, ... ... Vonderheide RH, et al. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discovery. PMID 33727309 DOI: 10.1158/2159-8290.CD-20-0841 |
0.343 |
|
| 2021 |
Huang A, Bange E, Han N, Wileyto EP, Kim J, Gouma S, Robinson J, Greenplate A, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman A, Ittner C, ... ... Vonderheide R, et al. CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Research Square. PMID 33564756 DOI: 10.21203/rs.3.rs-162289/v1 |
0.388 |
|
| 2021 |
Janowitz T, Kleeman S, Vonderheide RH. Reconsidering dexamethasone for anti-emesis when combining chemotherapy and immunotherapy. The Oncologist. PMID 33465258 DOI: 10.1002/onco.13680 |
0.304 |
|
| 2021 |
O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, ... ... Vonderheide RH, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet. Oncology. 22: 118-131. PMID 33387490 DOI: 10.1016/S1470-2045(20)30532-5 |
0.603 |
|
| 2020 |
Vonderheide RH, Bear AS. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Frontiers in Immunology. 11: 605619. PMID 33304355 DOI: 10.3389/fimmu.2020.605619 |
0.456 |
|
| 2020 |
Reiss KA, Wattenberg MM, Damjanov N, Prechtel Dunphy E, Jacobs-Small M, Lubas MJ, Robinson J, Dicicco L, Garcia-Marcano L, Giannone MA, Karasic TB, Furth EE, Carpenter EL, Wojcieszynski AP, Vonderheide RH, et al. A Pilot Study of Galunisertib Plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Molecular Cancer Therapeutics. PMID 33268571 DOI: 10.1158/1535-7163.MCT-20-0632 |
0.61 |
|
| 2020 |
Li J, Yuan S, Norgard RJ, Yan F, Sun YH, Kim IK, Merrell AJ, Sela Y, Jiang Y, Bhanu NV, Garcia BA, Vonderheide RH, Blanco A, Stanger BZ. Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer. Cancer Discovery. PMID 33158848 DOI: 10.1158/2159-8290.CD-20-0519 |
0.392 |
|
| 2020 |
Bear AS, Vonderheide RH, O'Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell. PMID 32946773 DOI: 10.1016/J.Ccell.2020.08.004 |
0.515 |
|
| 2020 |
Lin JH, Huffman AP, Wattenberg MM, Walter DM, Carpenter EL, Feldser DM, Beatty GL, Furth EE, Vonderheide RH. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. The Journal of Experimental Medicine. 217. PMID 32453421 DOI: 10.1084/Jem.20190673 |
0.686 |
|
| 2020 |
Luo LY, O'Hara MH, Mitchell TC, Vonderheide RH, Wherry EJ, Minn AJ, Maity A. Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Seminars in Radiation Oncology. 30: 173-180. PMID 32381296 DOI: 10.1016/J.Semradonc.2019.12.007 |
0.394 |
|
| 2020 |
Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. CCL5 mediates CD40-driven CD4+ T-cell tumor infiltration and immunity. Jci Insight. PMID 32324594 DOI: 10.1172/Jci.Insight.137263 |
0.525 |
|
| 2020 |
Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, et al. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32273276 DOI: 10.1158/1078-0432.Ccr-19-3978 |
0.408 |
|
| 2020 |
Morrison AH, Diamond MS, Hay CA, Byrne KT, Vonderheide RH. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. PMID 32213589 DOI: 10.1073/Pnas.1918971117 |
0.557 |
|
| 2020 |
Shah PD, Huang ACC, Xu X, Zhang PJ, Orlowski R, Matlawski T, Shea J, Cervini A, Amaravadi RK, Tchou JC, Schuchter LM, Wherry EJ, Linette GP, Mick R, Kulikovskaya I, ... ... Vonderheide RH, et al. Phase I trial of autologous cMET-directed CAR-t cells administered intravenously in patients with melanoma & breast carcinoma. Journal of Clinical Oncology. 38: 10035-10035. DOI: 10.1200/Jco.2020.38.15_Suppl.10035 |
0.412 |
|
| 2020 |
Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin J, Sun YH, Liudahl SM, Tobias JW, Lowe S, Coussens LM, Wherry JE, Vonderheide RH, et al. Abstract PR11: Tumor cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr11 |
0.586 |
|
| 2020 |
Lin JH, Vonderheide RH. Abstract LB-077: Dendritic cell dysfunction precedes tumor formation during pancreatic oncogenesis Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-077 |
0.567 |
|
| 2019 |
Richman LP, Vonderheide RH, Rech AJ. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade. Cell Systems. PMID 31606370 DOI: 10.1016/J.Cels.2019.08.009 |
0.361 |
|
| 2019 |
Vonderheide RH. CD40 Agonist Antibodies in Cancer Immunotherapy. Annual Review of Medicine. PMID 31412220 DOI: 10.1146/Annurev-Med-062518-045435 |
0.521 |
|
| 2019 |
Mastio J, Condamine T, Dominguez G, Kossenkov AV, Donthireddy L, Veglia F, Lin C, Wang F, Fu S, Zhou J, Viatour P, Lavilla-Alonso S, Polo AT, Tcyganov EN, Mulligan C, ... ... Vonderheide RH, et al. Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. The Journal of Experimental Medicine. PMID 31239386 DOI: 10.1084/Jem.20181952 |
0.461 |
|
| 2019 |
Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, Quinones L, Sela Y, Yamazoe T, Gordon N, Tobias JW, Byrne KT, Rech AJ, FitzGerald GA, Stanger BZ, ... Vonderheide RH, et al. Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). The Journal of Clinical Investigation. 130. PMID 31162144 DOI: 10.1172/Jci127755 |
0.545 |
|
| 2019 |
Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, To TKJ, Schug Z, Basu S, Wang F, Ricciotti E, DiRusso C, Murphy ME, Vonderheide RH, Lieberman PM, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. PMID 30996346 DOI: 10.1038/S41586-019-1118-2 |
0.37 |
|
| 2019 |
Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJ, Feldman M, Nayak A, Domchek SM, Vonderheide RH, et al. Genomic signatures predict the immunogenicity of BRCA-deficient breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30914433 DOI: 10.1158/1078-0432.Ccr-18-0468 |
0.355 |
|
| 2019 |
Byrne KT, Li J, Vonderheide RH, Stanger B. Abstract A054: Tumor cell intrinsic factors dictate immune cell infiltration and response to immunotherapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A054 |
0.589 |
|
| 2019 |
Byrne KT, Morrison AH, Vonderheide RH. Abstract PR04: STING and TLR-independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-Pr04 |
0.507 |
|
| 2019 |
Vonderheide RH. Abstract I12: CD40 immunotherapy for pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-I12 |
0.503 |
|
| 2019 |
Clendenin C, Sor R, McMenamin D, Stanger BZ, Beatty G, Vonderheide RH. Abstract C13: A “mouse hospital” for preclinical testing of diagnostic and treatment modalities in pancreatic ductal adenocarcinoma (PDA) Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-C13 |
0.454 |
|
| 2019 |
Markosyan N, Li J, Sun Y, Richman L, Lin J, Yan F, Quinones L, Sela Y, Yamazoe T, Gordon N, Tobias J, Byrne K, Rech A, FitzGerald G, Stanger B, ... Vonderheide R, et al. Abstract B33: Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) in pancreatic adenocarcinoma Immunotherapy. 79. DOI: 10.1158/1538-7445.Panca19-B33 |
0.562 |
|
| 2019 |
Lin JH, Huffman AP, Furth EE, Vonderheide RH. Abstract B31: Type 1 conventional dendritic cells are progressively and systemically dysregulated early in pancreatic carcinogenesis Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-B31 |
0.515 |
|
| 2019 |
Bear AS, Rech AJ, Richman LP, O'Hara MH, Linette GP, Carreno BM, Vonderheide RH. Abstract B04: Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer Immunotherapy. 79. DOI: 10.1158/1538-7445.Panca19-B04 |
0.493 |
|
| 2019 |
Li J, Byrne KT, Markosyan N, Yamazoe T, Yan F, Chen Z, Sun YH, Lin J, Sela Y, Norgard RJ, Yuan S, Merrell AJ, Tobias JW, Vonderheide RH, Stanger BZ. Abstract A28: Investigation of tumor-cell-intrinsic factors regulating immune infiltration and response to immunotherapy in pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-A28 |
0.589 |
|
| 2019 |
O'Hara MH, O'Reilly EM, Rosemarie M, Varadhachary G, Wainberg ZA, Ko A, Fisher GA, Rahma O, Lyman JP, Cabanski CR, Carpenter EL, Hollmann T, Gherardini PF, Kitch L, Selinsky C, ... ... Vonderheide RH, et al. Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct004 |
0.64 |
|
| 2018 |
Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, Lin C, Alicea-Torres K, Sehgal M, Nefedova Y, Zhou J, Languino LR, Clendenin C, Vonderheide RH, Mulligan C, et al. Unique pattern of neutrophil migration and function during tumor progression. Nature Immunology. PMID 30323345 DOI: 10.1038/S41590-018-0229-5 |
0.443 |
|
| 2018 |
Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, ... ... Vonderheide RH, et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 7: e1468956. PMID 30288340 DOI: 10.1080/2162402X.2018.1468956 |
0.411 |
|
| 2018 |
Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, ... ... Vonderheide RH, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. PMID 29958801 DOI: 10.1016/J.Immuni.2018.06.006 |
0.581 |
|
| 2018 |
Lee KE, Spata M, Maduka R, Vonderheide RH, Simon MC. Hif1α Deletion Limits Tissue Regeneration via Aberrant B Cell Accumulation in Experimental Pancreatitis. Cell Reports. 23: 3457-3464. PMID 29924990 DOI: 10.1016/J.Celrep.2018.05.071 |
0.358 |
|
| 2018 |
Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends in Cancer. 4: 418-428. PMID 29860986 DOI: 10.1016/J.Trecan.2018.04.001 |
0.397 |
|
| 2018 |
Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH. Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer. Cancer Research. PMID 29844122 DOI: 10.1158/0008-5472.Can-17-3821 |
0.547 |
|
| 2018 |
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine. PMID 29686425 DOI: 10.1038/S41591-018-0014-X |
0.46 |
|
| 2018 |
Vonderheide RH. The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell. 33: 563-569. PMID 29634944 DOI: 10.1016/J.Ccell.2018.03.008 |
0.547 |
|
| 2018 |
Rech AJ, Balli D, Mantero A, Ishwaran H, Nathanson KL, Stanger BZ, Vonderheide RH. Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunology Research. PMID 29339376 DOI: 10.1158/2326-6066.Cir-17-0559 |
0.515 |
|
| 2018 |
Reiss KA, Ben-Josef E, Damjanov N, Hoteit M, O'Hara MH, Karasic TB, Teitelbaum UR, Schneider C, O'Dwyer PJ, Carpenter EL, Mick R, Vonderheide RH. A pilot study of galunisertib (LY2157299) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 36: TPS528-TPS528. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps528 |
0.668 |
|
| 2018 |
Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Lunceford N, Barrett A, Mitra N, Morrissette JJD, Nayak A, Feldman M, Domchek SM, Vonderheide RH, Nathanson KL. Abstract A22: Homologous recombination deficiency negatively predicts for immune infiltration and antitumor immune activity in breast tumors with BRCA1/2 alterations Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A22 |
0.445 |
|
| 2018 |
Morrison AH, Byrne KT, Vonderheide RH. Abstract 4940: Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma Cancer Research. 78: 4940-4940. DOI: 10.1158/1538-7445.Am2018-4940 |
0.532 |
|
| 2018 |
Byrne KT, Li J, Vonderheide RH, Stanger BZ. Abstract 1011: Tumor cell intrinsic factors dictate T cell infiltration and therapeutic response in pancreatic ductal adenocarcinoma Tumor Biology. DOI: 10.1158/1538-7445.Am2018-1011 |
0.52 |
|
| 2017 |
Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, ... ... Vonderheide RH, et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell. 32: 654-668.e5. PMID 29136508 DOI: 10.1016/J.Ccell.2017.10.005 |
0.467 |
|
| 2017 |
Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey A, Williams AD, So A, Conejo-Garcia JR, Plesa G, ... ... Vonderheide RH, et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunology Research. PMID 29109077 DOI: 10.1158/2326-6066.Cir-17-0189 |
0.514 |
|
| 2017 |
Huffman AP, Richman LP, Crisalli L, Ganetsky A, Porter DL, Vonderheide RH, Reshef R. Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as GVHD Prophylaxis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29061535 DOI: 10.1016/J.Bbmt.2017.10.028 |
0.364 |
|
| 2017 |
Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for Breast Cancer: What Are We Missing? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 2640-2646. PMID 28572258 DOI: 10.1158/1078-0432.Ccr-16-2569 |
0.424 |
|
| 2017 |
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, ... ... Vonderheide RH, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. PMID 28397821 DOI: 10.1038/Nature22079 |
0.399 |
|
| 2017 |
Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, Mueller C, Flotte TR, Wilson JM. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency. Proceedings of the National Academy of Sciences of the United States of America. PMID 28137880 DOI: 10.1073/Pnas.1617726114 |
0.36 |
|
| 2017 |
Moy RH, Huffman AP, Richman LP, Crisalli L, Wang XK, Hoxie JA, Mick R, Emerson SG, Zhang Y, Vonderheide RH, Porter DL, Reshef R. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood. PMID 28057639 DOI: 10.1182/Blood-2016-08-735076 |
0.417 |
|
| 2017 |
Kraya A, Maxwell KN, Wenz BM, Wubbenhorst B, Sloover DD, Lunceford N, Barrett A, Morrissette JD, Feldman M, Vonderheide RH, Domcheck SM, Nathanson KL. Abstract A12: Analysis of tumor immunogenicity in germline BRCA1/2 mutation associated breast and ovarian cancers Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-A12 |
0.371 |
|
| 2017 |
Tchou J, Zhang P, Levine B, Zhao Y, Matro J, DeMichele A, Amy C, Schuchter L, Plesa G, Vonderheide R, June C. Abstract P6-10-08: Preliminary results of a first in human Phase 1 clinical trial to demonstrate safety and feasibility of chimeric antigen receptor T (CART) cells directed against c-Met in the treatment of breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-10-08 |
0.365 |
|
| 2017 |
Vonderheide RH. Abstract SY25-02: Antigenic strength vs. tumor microenvironment in determining cancer immunosurveillance Immunology. 77. DOI: 10.1158/1538-7445.Am2017-Sy25-02 |
0.458 |
|
| 2017 |
Kraya A, Maxwell KN, Wenz BM, Wubbenhorst B, Lunceford N, Barrett A, Morrissette JJ, Feldman MD, Domchek SM, Vonderheide RH, Nathanson KL. Abstract 3691: Analysis of germline BRCA1/2 mutation associated breast and ovarian tumors reveals distinct pathways of immunosuppression Immunology. 77: 3691-3691. DOI: 10.1158/1538-7445.Am2017-3691 |
0.333 |
|
| 2016 |
Balli D, Rech AJ, Stanger BZ, Vonderheide RH. Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28007776 DOI: 10.1158/1078-0432.Ccr-16-2128 |
0.39 |
|
| 2016 |
Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DS, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, ... Vonderheide RH, et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell. 167: 1540-1554.e12. PMID 27912061 DOI: 10.1016/J.Cell.2016.11.022 |
0.418 |
|
| 2016 |
Chao T, Furth EE, Vonderheide RH. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research. PMID 27737879 DOI: 10.1158/2326-6066.Cir-16-0188 |
0.524 |
|
| 2016 |
Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, Byrne KT, Stanger BZ, Riley JL, Markosyan N, Winograd R, Vonderheide RH. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. Jci Insight. 1. PMID 27642636 DOI: 10.1172/Jci.Insight.88328 |
0.536 |
|
| 2016 |
Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ. Metastatic progression is associated with dynamic changes in the local microenvironment. Nature Communications. 7: 12819. PMID 27628423 DOI: 10.1038/Ncomms12819 |
0.341 |
|
| 2016 |
Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications. 7: 12150. PMID 27381735 DOI: 10.1038/Ncomms12150 |
0.417 |
|
| 2016 |
Byrne KT, Vonderheide RH. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Reports. PMID 27292635 DOI: 10.1016/J.Celrep.2016.05.058 |
0.55 |
|
| 2016 |
Byrne KT, Leisenring NH, Bajor DL, Vonderheide RH. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. Journal of Immunology (Baltimore, Md. : 1950). PMID 27217585 DOI: 10.4049/Jimmunol.1600146 |
0.482 |
|
| 2016 |
Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research. 4: 279-88. PMID 27036972 DOI: 10.1158/2326-6066.Cir-16-0045 |
0.3 |
|
| 2016 |
Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, et al. Infusion of CD3/CD28 co-stimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American Journal of Hematology. PMID 26858124 DOI: 10.1002/Ajh.24303 |
0.394 |
|
| 2016 |
Le DT, Crocenzi TS, Uram JN, Lutz ER, Laheru D, Sugar EA, Vonderheide RH, Fisher GA, Ko AH, Murphy AL, McDougall K, Ferber S, Brockstedt DG, Jaffee EM. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). Journal of Clinical Oncology. 34: TPS486-TPS486. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps486 |
0.501 |
|
| 2016 |
Siolas D, Cullis J, Avanzi A, Byrne K, Leichman LP, Vonderheide RH, Bar-Sagi D. Antitumor activity and immune reponse in CD40 immunotherapy with gemcitabine and nab-paclitaxel in an orthotopic pancreatic cancer mouse model. Journal of Clinical Oncology. 34: 271-271. DOI: 10.1200/Jco.2016.34.4_Suppl.271 |
0.511 |
|
| 2016 |
Bendell JC, Fakih M, Infante JR, Bajor DL, Cristea MC, Tremblay T, Trifan OC, Vonderheide RH. Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors. Journal of Clinical Oncology. 34: TPS3110-TPS3110. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3110 |
0.471 |
|
| 2016 |
Vonderheide RH. Abstract IA45: Prospect of a vaccine to prevent cancer in BRCA1-2 mutation carriers Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Ia45 |
0.494 |
|
| 2016 |
Byrne KT, Vonderheide RH. Abstract A076: CD40 stimulation overrides role of innate immune sensors for priming of T cells in cancer Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A076 |
0.485 |
|
| 2016 |
Victor CT, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Benci J, Xu B, Dada H, Odorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi R, Schuchter L, ... ... Vonderheide R, et al. Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A056 |
0.446 |
|
| 2016 |
Markosyan N, Rech A, Vonderheide R. Abstract A094: mPGES1 deletion increases tumor susceptibility to immune suppression Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A094 |
0.425 |
|
| 2016 |
Balli D, Rech AJ, Stanger BZ, Vonderheide RH. Abstract IA23: Immune landscape of human pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-Ia23 |
0.443 |
|
| 2016 |
Victor CT, Rech A, Benci J, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odorizzi P, Herati R, Amaravadi R, Schuchter L, Ishwaran H, Mick R, ... ... Vonderheide R, et al. Abstract PR05: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-Pr05 |
0.416 |
|
| 2016 |
Kraya AA, Maxwell KN, Wenz BM, Wubbenhorst B, DeSloover D, Lunceford N, Morrissette JD, Feldman M, Vonderheide RH, Domchek SM, Nathanson KL. Abstract 4511: Characterization of tumor neoantigen repertoire in patients with germline BRCA1/2 mutations Cancer Research. 76: 4511-4511. DOI: 10.1158/1538-7445.Am2016-4511 |
0.391 |
|
| 2015 |
Lee KE, Spata M, Bayne LJ, Buza EL, Durham AC, Allman D, Vonderheide RH, Simon MC. Hif1α deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia. Cancer Discovery. PMID 26715642 DOI: 10.1158/2159-8290.Cd-15-0822 |
0.807 |
|
| 2015 |
Vonderheide RH. CD47 blockade as another immune checkpoint therapy for cancer. Nature Medicine. 21: 1122-3. PMID 26444633 DOI: 10.1038/Nm.3965 |
0.551 |
|
| 2015 |
Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, ... Vonderheide RH, et al. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26056179 DOI: 10.1200/Jco.2014.60.1203 |
0.347 |
|
| 2015 |
Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, et al. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Research. 75: 2800-10. PMID 25979873 DOI: 10.1158/0008-5472.Can-14-3041 |
0.564 |
|
| 2015 |
Byrne KT, Vonderheide RH, Jaffee EM, Armstrong TD. Special Conference on Tumor Immunology and Immunotherapy: A New Chapter. Cancer Immunology Research. PMID 25968457 DOI: 10.1158/2326-6066.Cir-15-0106 |
0.485 |
|
| 2015 |
Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology. 149: 201-10. PMID 25888329 DOI: 10.1053/J.Gastro.2015.04.010 |
0.51 |
|
| 2015 |
Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: Optimal dose and fractionation. Cancer Letters. PMID 25799953 DOI: 10.1016/J.Canlet.2015.03.024 |
0.336 |
|
| 2015 |
Karimi MA, Bryson JL, Richman LP, Fesnak AD, Leichner TM, Satake A, Vonderheide RH, Raulet DH, Reshef R, Kambayashi T. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. Blood. 125: 3655-63. PMID 25788701 DOI: 10.1182/Blood-2015-02-629006 |
0.468 |
|
| 2015 |
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, ... ... Vonderheide RH, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 520: 373-7. PMID 25754329 DOI: 10.1038/Nature14292 |
0.434 |
|
| 2015 |
Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research. 3: 399-411. PMID 25678581 DOI: 10.1158/2326-6066.Cir-14-0215 |
0.529 |
|
| 2015 |
Siolas D, Aristizabal O, Byrne K, Leichman LP, Vonderheide RH, Bar-Sagi D. Preclinical immunotherapy studies using an orthotopic pancreatic cancer mouse model. Journal of Clinical Oncology. 33: 324-324. DOI: 10.1200/Jco.2015.33.3_Suppl.324 |
0.473 |
|
| 2015 |
Vonderheide RH, Aggarwal C, Bajor DL, Goldenberg J, Loch C, Lee JC, Yan J, Morrow MP, DeMichele A, Langer CJ, O'Dwyer PJ, Weiner DB, Yang Z, Bagarazzi ML. Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy. Journal of Clinical Oncology. 33: TPS3104-TPS3104. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps3104 |
0.454 |
|
| 2015 |
Moy RH, Huffman AP, Richman LP, Crisalli L, Hoxie JA, Vonderheide RH, Porter DL, Reshef R. Immunologic Effects of CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis Blood. 126: 920-920. DOI: 10.1182/Blood.V126.23.920.920 |
0.461 |
|
| 2015 |
Byrne KT, Vonderheide RH. Abstract PR07: Agonistic CD40 antibody combined with chemotherapy drives TLR4/MyD88 independent regression of pancreatic tumors in a T cell dependent manner Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Pr07 |
0.562 |
|
| 2015 |
Vonderheide RH. Abstract IA05: Breaking immune privilege in pancreatic cancer Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Ia05 |
0.525 |
|
| 2015 |
Rech AJ, Twyman C, Maity A, Rengan R, Pauken KE, Stelekati E, Xu B, Dada H, Odorizzi PM, Herati RD, Mansfield KD, Patsch D, Amaravadi R, Schuchter L, Ishwaran H, ... ... Vonderheide RH, et al. Abstract A52: Radiation and dual PD-L1 and CTLA4 checkpoint blockade non-redundantly improves tumor resistance, response, and immunity Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A52 |
0.496 |
|
| 2015 |
Bajor DL, Mick R, Riese MJ, Lee RP, Xu X, Torigian DA, Stelekati E, Sweeney M, Sullivan BJ, Schuchter LM, Amaravadi R, Wherry EJ, Vonderheide RH. Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A38 |
0.424 |
|
| 2015 |
Mick R, Bajor D, Richman L, Vonderheide R. Abstract A10: Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (αCD40) and anti-CTLA4 monoclonal antibody tremelimumab Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A10 |
0.356 |
|
| 2015 |
Commisso C, Ramirez C, Soydaner-Azeloglu R, Bajor DL, Vonderheide RH, Bar-Sagi D. Abstract PR08: Pulling out all the stops: Exploiting macropinocytosis inhibition for the treatment of pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-Pr08 |
0.491 |
|
| 2015 |
Reichert M, Bakir BS, Hahn CM, Botta GP, Rhim AD, Vonderheide RH, Reynolds AB, Bi Y, Davuluri R, Saka B, Adsay NV, Rustgi AK. Abstract PR05: p120 catenin mediated epithelial-to-mesenchymal plasticity determines the metastatic potential of pancreatic ductal adenocarcinoma Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-Pr05 |
0.362 |
|
| 2015 |
Domchek SM, McWilliams R, Hendifar A, Shroff RT, Leichman L, Epelbaum R, Geva R, Kim G, Alberts SR, Wolff RA, Allen A, Giordano H, Raponi M, Isaacson J, Rolfe L, ... ... Vonderheide RH, et al. Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B102 |
0.373 |
|
| 2015 |
Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, Magliano MPd. Abstract A48: CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A48 |
0.369 |
|
| 2015 |
Vonderheide RH. Abstract SY21-04: Starting an immune response against pancreatic cancer: Getting past the stroma Immunology. 75. DOI: 10.1158/1538-7445.Am2015-Sy21-04 |
0.377 |
|
| 2015 |
Bajor DL, Mick R, Riese MJ, Richman LP, Xu X, Torigian DA, Stelekati E, Sweeney M, Sullivan B, Schuchter LM, Amaravadi R, Wherry EJ, Vonderheide RH. Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct137 |
0.432 |
|
| 2015 |
Aiello NM, Bajor DL, Pham MN, Vonderheide RH, Stanger BZ. Abstract 5176: Chemotherapy alters the natural history of metastatic progression Cancer Research. 75: 5176-5176. DOI: 10.1158/1538-7445.Am2015-5176 |
0.391 |
|
| 2015 |
Markosyan N, Rech A, Vonderheide RH, FitzGerald GA, Smyth EM. Abstract 469: mPGES1 deletion and the mechanisms of tumor growth suppression Cancer Research. 75: 469-469. DOI: 10.1158/1538-7445.Am2015-469 |
0.368 |
|
| 2015 |
Lo A, Wang LS, Scholler J, Monslow J, Avery D, Evans RA, Bajor DJ, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E. Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia Immunology. 75: 3187-3187. DOI: 10.1158/1538-7445.Am2015-3187 |
0.429 |
|
| 2015 |
Rech AJ, Victor CT, Maity A, Rengan R, Pauken KE, Stelekati E, Benci J, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, ... ... Vonderheide RH, et al. Abstract 2858: Radiation and dual immune checkpoint blockade overcome tumor resistance and distinctly improve immunity Cancer Research. 75: 2858-2858. DOI: 10.1158/1538-7445.Am2015-2858 |
0.518 |
|
| 2015 |
Byrne KT, Vonderheide RH. Abstract 1356: Chemotherapy and agonistic CD40 cooperate to regress pancreatic adenocarcinoma independently of TLR4 and MyD88 Cancer Research. 75: 1356-1356. DOI: 10.1158/1538-7445.Am2015-1356 |
0.45 |
|
| 2015 |
Reshef R, Huffman AP, Gao A, Sell M, Luskin MR, Luger S, Loren A, Hexner EO, Nasta SD, Frey NV, Gill S, Mangan J, Richman LP, Kambayashi T, Stadtmauer EA, ... Vonderheide RH, et al. A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content Biology of Blood and Marrow Transplantation. 21: S42-S43. DOI: 10.1016/J.Bbmt.2014.11.036 |
0.324 |
|
| 2014 |
Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunology Research. 2: 1051-8. PMID 25252722 DOI: 10.1158/2326-6066.Cir-14-0154 |
0.519 |
|
| 2014 |
Richman LP, Vonderheide RH. Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. Oncoimmunology. 3: e28610. PMID 25097801 DOI: 10.4161/Onci.28610 |
0.377 |
|
| 2014 |
Vonderheide RH. Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras. Cancer Cell. 25: 553-4. PMID 24823632 DOI: 10.1016/J.Ccr.2014.04.020 |
0.381 |
|
| 2014 |
Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, di Magliano MP. CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunology Research. 2: 423-35. PMID 24795355 DOI: 10.1158/2326-6066.Cir-14-0016-T |
0.481 |
|
| 2014 |
Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. The Journal of Clinical Investigation. 124: 2626-39. PMID 24789911 DOI: 10.1172/Jci74056 |
0.458 |
|
| 2014 |
Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nature Reviews. Clinical Oncology. 11: 91-9. PMID 24445516 DOI: 10.1038/Nrclinonc.2013.245 |
0.401 |
|
| 2014 |
Richman LP, Vonderheide RH. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunology Research. 2: 19-26. PMID 24416732 DOI: 10.1158/2326-6066.Cir-13-0152 |
0.392 |
|
| 2014 |
Vonderheide RH, June CH. Engineering T cells for cancer: our synthetic future. Immunological Reviews. 257: 7-13. PMID 24329786 DOI: 10.1111/Imr.12143 |
0.54 |
|
| 2014 |
Reshef R, Mangan JK, Luger SM, Loren AW, Hexner EO, Frey NV, Stadtmauer EA, Blauser RE, Richman LP, Huffman AP, Ganetsky A, Acosta EP, Hoxie JA, Mick R, Vonderheide RH, et al. Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study Blood. 124: 2491-2491. DOI: 10.1182/Blood.V124.21.2491.2491 |
0.333 |
|
| 2014 |
Reshef R, Huffman AP, Gao A, Sell M, Luskin MR, Luger SM, Loren AW, Hexner EO, Nasta SD, Frey NV, Gill SI, Mangan J, Richman LP, Kambayashi T, Stadtmauer EA, ... Vonderheide RH, et al. CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation Blood. 124: 1260-1260. DOI: 10.1182/Blood.V124.21.1260.1260 |
0.381 |
|
| 2014 |
Zhang Y, Yan W, Bednar F, Wan S, Collins MA, Evans RA, Mathew E, Welling TH, Vonderheide RH, Magliano MPd. Abstract IA12: Oncogenic KRAS and the inflammatory microenvironment in pancreatic cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Ia12 |
0.512 |
|
| 2014 |
Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, Magliano MPd. Abstract B23: CD4+ T lymphocytes promote pancreatic cancer progression by suppressing anti-tumor immune responses Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B23 |
0.547 |
|
| 2013 |
Rech AJ, Vonderheide RH. Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment. Cancer Discovery. 3: 1330-2. PMID 24327693 DOI: 10.1158/2159-8290.Cd-13-0775 |
0.469 |
|
| 2013 |
Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, ... ... Vonderheide RH, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. The Journal of Clinical Investigation. 123: 5310-8. PMID 24231351 DOI: 10.1172/Jci70314 |
0.353 |
|
| 2013 |
Bayne LJ, Vonderheide RH. Multicolor flow cytometric analysis of immune cell subsets in tumor-bearing mice. Cold Spring Harbor Protocols. 2013: 955-60. PMID 24086051 DOI: 10.1101/Pdb.Prot077198 |
0.818 |
|
| 2013 |
Bayne LJ, Vonderheide RH. Methods for analysis of the immune system in mouse cancer models. Cold Spring Harbor Protocols. 2013: 901-3. PMID 24086048 DOI: 10.1101/Pdb.Top069971 |
0.813 |
|
| 2013 |
Vonderheide RH, Nathanson KL. Immunotherapy at large: the road to personalized cancer vaccines. Nature Medicine. 19: 1098-100. PMID 24013748 DOI: 10.1038/Nm.3317 |
0.498 |
|
| 2013 |
Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Research : Bcr. 15: R75. PMID 24004819 DOI: 10.1186/Bcr3469 |
0.563 |
|
| 2013 |
Bayne LJ, Vonderheide RH. A myeloid-derived suppressor cell-mediated T-cell suppression assay for functional evaluation of immune cells in tumor-bearing mice. Cold Spring Harbor Protocols. 2013: 849-53. PMID 24003206 DOI: 10.1101/Pdb.Prot077214 |
0.811 |
|
| 2013 |
Bayne LJ, Vonderheide RH. Immunohistochemical assessment of immune cells in mouse tumor tissue. Cold Spring Harbor Protocols. 2013: 843-8. PMID 24003205 DOI: 10.1101/Pdb.Prot077206 |
0.777 |
|
| 2013 |
Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6286-95. PMID 23983255 DOI: 10.1158/1078-0432.Ccr-13-1320 |
0.345 |
|
| 2013 |
Byrne KT, Vonderheide RH. CD40 therapy and surgery: a potential immunologic partnership. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 359-61. PMID 23924786 DOI: 10.1097/Cji.0B013E31829Fb871 |
0.548 |
|
| 2013 |
Ansell SM, Vonderheide RH. Cellular composition of the tumor microenvironment. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. PMID 23714465 DOI: 10.1200/EdBook_AM.2013.33.e91 |
0.386 |
|
| 2013 |
Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL. CD40 immunotherapy for pancreatic cancer. Cancer Immunology, Immunotherapy : Cii. 62: 949-54. PMID 23589109 DOI: 10.1007/S00262-013-1427-5 |
0.837 |
|
| 2013 |
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2: e23033. PMID 23483678 DOI: 10.4161/Onci.23033 |
0.483 |
|
| 2013 |
Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1035-43. PMID 23460534 DOI: 10.1158/1078-0432.Ccr-12-2064 |
0.509 |
|
| 2013 |
Vonderheide RH, Bayne LJ. Inflammatory networks and immune surveillance of pancreatic carcinoma. Current Opinion in Immunology. 25: 200-5. PMID 23422836 DOI: 10.1016/J.Coi.2013.01.006 |
0.833 |
|
| 2013 |
Twyman C, Rech A, Rengan R, Vonderheide R, Minn A. Stereotactic body radiation therapy and CTLA-4 blockade as a novel therapy for advanced melanoma Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P118 |
0.465 |
|
| 2013 |
Beatty GL, Winograd R, Evans R, Luque SL, Guirnalda P, Vonderheide RH. Abstract PR4: Restoring T cell immuno-surveillance in pancreatic carcinoma using CD40 agonists. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Pr4 |
0.597 |
|
| 2013 |
Aiello NM, Bajor DL, Vonderheide RH, Stanger BZ. Abstract PR14: Lineage labeling elucidates the natural history of metastatic colonization Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-Pr14 |
0.404 |
|
| 2013 |
Vonderheide RH. Abstract SY09-01: Inflammatory networks and cancer immune surveillance. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy09-01 |
0.57 |
|
| 2012 |
Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21: 822-35. PMID 22698406 DOI: 10.1016/J.Ccr.2012.04.025 |
0.835 |
|
| 2012 |
Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, ... Vonderheide RH, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Science Translational Medicine. 4: 134ra62. PMID 22593175 DOI: 10.1126/Scitranslmed.3003330 |
0.472 |
|
| 2012 |
Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, ... ... Vonderheide RH, et al. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood. 119: 2956-9. PMID 22289893 DOI: 10.1182/Blood-2011-09-378398 |
0.523 |
|
| 2012 |
Bajor DL, Vonderheide RH. Rehabilitation for oncogene addiction: role of immunity in cellular sobriety. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1192-4. PMID 22266272 DOI: 10.1158/1078-0432.Ccr-11-3322 |
0.412 |
|
| 2012 |
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. EMT and dissemination precede pancreatic tumor formation. Cell. 148: 349-61. PMID 22265420 DOI: 10.1016/J.Cell.2011.11.025 |
0.417 |
|
| 2012 |
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy : Cii. 61: 629-41. PMID 22021066 DOI: 10.1007/S00262-011-1081-8 |
0.356 |
|
| 2012 |
Doi H, Iyer TK, Carpenter E, Li H, Chang KM, Vonderheide RH, Kaplan DE. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology (Baltimore, Md.). 55: 709-19. PMID 21932384 DOI: 10.1002/Hep.24689 |
0.636 |
|
| 2012 |
Beatty GL, Winograd R, Evans RA, Vonderheide RH. Abstract IA9: Immune surveillance and CD40 therapy of pancreatic cancer in mice and humans. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-Ia9 |
0.595 |
|
| 2012 |
Vonderheide RH. Abstract SY40-01: Anti-CD40 as an anticancer agent Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy40-01 |
0.573 |
|
| 2011 |
Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. Plos One. 6: e24167. PMID 21904611 DOI: 10.1371/Journal.Pone.0024167 |
0.453 |
|
| 2011 |
Stairs DB, Bayne LJ, Rhoades B, Vega ME, Waldron TJ, Kalabis J, Klein-Szanto A, Lee JS, Katz JP, Diehl JA, Reynolds AB, Vonderheide RH, Rustgi AK. Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell. 19: 470-83. PMID 21481789 DOI: 10.1016/J.Ccr.2011.02.007 |
0.811 |
|
| 2011 |
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (New York, N.Y.). 331: 1612-6. PMID 21436454 DOI: 10.1126/Science.1198443 |
0.573 |
|
| 2011 |
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, ... ... Vonderheide RH, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 117: 788-97. PMID 21030558 DOI: 10.1182/Blood-2010-08-299396 |
0.502 |
|
| 2011 |
Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood. 117: 63-71. PMID 20864577 DOI: 10.1182/Blood-2010-07-296822 |
0.417 |
|
| 2011 |
Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Goldstein SC, Nasta SD, Stadtmauer EA, Smith J, Mick R, Heitjan DF, Hoxie JA, Emerson SG, Vonderheide RH, Porter DL. Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study Blood. 118: 1011-1011. DOI: 10.1182/Blood.V118.21.1011.1011 |
0.319 |
|
| 2011 |
Doi H, Carpenter E, Vonderheide RH, Kaplan DE. Impaired Activation and Allostimulatory Capacity of B-Cells is Associated With Advanced but Not Early Stage Hepatitis C Gastroenterology. 140: S-900. DOI: 10.1016/S0016-5085(11)63735-9 |
0.583 |
|
| 2011 |
Stairs DB, Bayne LJ, Rhoades B, Vega ME, Nakagawa H, Klein-Szanto AJ, Katz JP, Reynolds AB, Vonderheide RH, Rustgi AK. Loss of P120-Catenin Results in Esophageal Tumorigenesis, Involving the Recruitment of Immature Myeloid Cells to the Tumor Microenvironment Gastroenterology. 140: S-182. DOI: 10.1016/S0016-5085(11)60735-X |
0.797 |
|
| 2010 |
Rüter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biology & Therapy. 10: 983-93. PMID 20855968 DOI: 10.4161/Cbt.10.10.13251 |
0.418 |
|
| 2010 |
Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer Journal (Sudbury, Mass.). 16: 342-7. PMID 20693845 DOI: 10.1097/Ppo.0B013E3181Eb336D |
0.501 |
|
| 2010 |
Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3485-94. PMID 20479064 DOI: 10.1158/1078-0432.Ccr-10-0505 |
0.423 |
|
| 2010 |
Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, Wang X, Heitjan DF, Litzky L, June CH, Vonderheide RH, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 852-60. PMID 20068553 DOI: 10.1038/Mt.2009.309 |
0.322 |
|
| 2010 |
Rech AJ, Mick R, Kaplan DE, Chang KM, Domchek SM, Vonderheide RH. Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy : Cii. 59: 599-607. PMID 19855964 DOI: 10.1007/S00262-009-0780-X |
0.461 |
|
| 2010 |
Beatty GL, Chiorean EG, Torigian DA, Teitelbaum UR, Sun W, Fly KD, Huhn RD, Vonderheide RH, O'Dwyer PJ. A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer. Journal of Clinical Oncology. 28: 2539-2539. DOI: 10.1200/Jco.2010.28.15_Suppl.2539 |
0.411 |
|
| 2010 |
Rech AJ, Mick R, Recio A, DeMichele A, Tweed CK, Fox KR, Domchek SM, Vonderheide RH. Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology. 28: 2508-2508. DOI: 10.1200/Jco.2010.28.15_Suppl.2508 |
0.476 |
|
| 2010 |
Reshef R, Luger SM, Loren AW, Frey NV, Goldstein SC, Hexner EO, Stadtmauer EA, Smith J, Mick R, Heitjan DF, Shetzline SE, Danet-Desnoyers GH, Emerson SG, Hoxie JA, Vonderheide RH, et al. Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist Blood. 116: 673-673. DOI: 10.1182/Blood.V116.21.673.673 |
0.392 |
|
| 2010 |
Stairs D, Bayne LJ, Rhoades B, Mui KL, Kalabis J, Nakagawa H, Wong GS, Grugan KD, Klein-Szanto AJ, Lee J, Katz JP, Vonderheide RH, Reynolds AB, Rustgi AK. 847g Inactivation of the P120-Catenin Gene Results in a Tumor Microenvironment With Inflammation and Cancer That Establishes Its Identity as a Bone Fide Tumor Suppressor Gastroenterology. 138: S-112. DOI: 10.1016/S0016-5085(10)60513-6 |
0.783 |
|
| 2009 |
Carpenter EL, Mick R, Rüter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. Journal of Translational Medicine. 7: 93. PMID 19906293 DOI: 10.1186/1479-5876-7-93 |
0.705 |
|
| 2009 |
Reid GS, Shan X, Coughlin CM, Lassoued W, Pawel BR, Wexler LH, Thiele CJ, Tsokos M, Pinkus JL, Pinkus GS, Grupp SA, Vonderheide RH. Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6602-8. PMID 19825945 DOI: 10.1158/1078-0432.Ccr-09-0829 |
0.508 |
|
| 2009 |
Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Annals of the New York Academy of Sciences. 1174: 99-106. PMID 19769742 DOI: 10.1111/J.1749-6632.2009.04939.X |
0.513 |
|
| 2009 |
Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA, Frey NV, Johnson FB, Porter DL, Vonderheide RH. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4944-53. PMID 19602548 DOI: 10.1158/1078-0432.Ccr-08-3332 |
0.469 |
|
| 2009 |
Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4277-87. PMID 19549767 DOI: 10.1158/1078-0432.Ccr-09-0537 |
0.696 |
|
| 2009 |
Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, Janofsky S, Yager K, Veloso E, Zheng Z, Milliron T, Westphal S, Cotte J, Huynh H, Cannon A, ... ... Vonderheide RH, et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4499-507. PMID 19509133 DOI: 10.1158/1078-0432.Ccr-09-0418 |
0.444 |
|
| 2009 |
Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Letters. 279: 1-7. PMID 19013709 DOI: 10.1016/J.Canlet.2008.09.037 |
0.462 |
|
| 2009 |
Vonderheide RH, LoRusso PM, Khalil M, Heath E, Khaira D, Soulieres D, Dorazio P, Mariani GL, Usari T, Domchek SM. Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer Journal of Clinical Oncology. 27: 3034-3034. DOI: 10.1200/Jco.2009.27.15_Suppl.3034 |
0.342 |
|
| 2009 |
Stadtmauer EA, Vogl DT, Aqui NA, Rapoport AP, Macdonald K, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso E, Levine B, Vonderheide RH, June CH, Sullivan K. Influenza (flu) Vaccine Administration to Patients with Multiple Myeloma (MM) Prior to Autologous T-Cell Harvest Leads to Better Reconstitution of Flu Immunity After High Dose Melphalan and Autologous Stem Cell Transplant (ASCT) and Reinfusion of Primed Ex-Vivo Co-Stimulated Autologous T-Cells and Post-ASCT Second Flu Vaccination Than Post-ASCT Flu Vaccination Alone. Blood. 114: 797-797. DOI: 10.1182/Blood.V114.22.797.797 |
0.403 |
|
| 2009 |
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang H, Janofsky S, Storek J, Chew A, Veloso E, Akpek G, Yanovich S, Tan MT, Wu Y, Cross A, Philip S, ... ... Vonderheide RH, et al. Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival. Blood. 114: 784-784. DOI: 10.1182/Blood.V114.22.784.784 |
0.43 |
|
| 2008 |
Aqui NA, Vonderheide RH. Survivin as a universal tumor antigen for novel cancer immunotherapy: functions of a killer clone. Cancer Biology & Therapy. 7: 1888-9. PMID 19158476 DOI: 10.4161/Cbt.7.12.7219 |
0.521 |
|
| 2008 |
Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Review of Vaccines. 7: 881-7. PMID 18767939 DOI: 10.1586/14760584.7.7.881 |
0.495 |
|
| 2008 |
Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, Clifford CA, Zurbriggen A, Sorenmo KU, Vonderheide RH. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Therapy. 15: 955-65. PMID 18337841 DOI: 10.1038/Gt.2008.22 |
0.527 |
|
| 2008 |
Carpenter EL, Vance BA, Klein RS, Voloschin A, Dalmau J, Vonderheide RH. Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. Journal of Neuroimmunology. 193: 173-82. PMID 18053582 DOI: 10.1016/J.Jneuroim.2007.10.014 |
0.689 |
|
| 2008 |
Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie. 90: 173-80. PMID 17716803 DOI: 10.1016/J.Biochi.2007.07.005 |
0.527 |
|
| 2007 |
Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update On Cancer Therapeutics. 2: 61-65. PMID 19587842 DOI: 10.1016/J.Uct.2007.06.001 |
0.55 |
|
| 2007 |
Chen DY, Vance BA, Thompson LB, Domchek SM, Vonderheide RH. Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. Cancer Biology & Therapy. 6: 1991-6. PMID 18087213 DOI: 10.4161/Cbt.6.12.5078 |
0.489 |
|
| 2007 |
Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A, Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Research. 67: 10546-55. PMID 17974999 DOI: 10.1158/0008-5472.Can-07-2765 |
0.726 |
|
| 2007 |
Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research. 67: 9518-27. PMID 17909062 DOI: 10.1158/0008-5472.Can-07-0175 |
0.559 |
|
| 2007 |
Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, ... ... Vonderheide RH, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4456-66. PMID 17671130 DOI: 10.1158/1078-0432.Ccr-07-0403 |
0.364 |
|
| 2007 |
Swoboda RK, Somasundaram R, Caputo L, Ochoa EM, Gimotty PA, Marincola FM, Van Belle P, Barth S, Elder D, Guerry D, Czerniecki B, Schuchter L, Vonderheide RH, Herlyn D. Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display. Cancer Research. 67: 3555-9. PMID 17440064 DOI: 10.1158/0008-5472.Can-06-2763 |
0.42 |
|
| 2007 |
Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 876-83. PMID 17327609 DOI: 10.1200/Jco.2006.08.3311 |
0.459 |
|
| 2007 |
Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1083-8. PMID 17317815 DOI: 10.1158/1078-0432.Ccr-06-1893 |
0.509 |
|
| 2007 |
Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Research. 67: 1842-52. PMID 17293384 DOI: 10.1158/0008-5472.Can-06-4038 |
0.466 |
|
| 2007 |
Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman A, Nunes FA, Lucey MR, Vance BA, Vonderheide RH, Reddy KR, McKeating JA, Chang KM. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology. 132: 654-66. PMID 17258733 DOI: 10.1053/J.Gastro.2006.11.044 |
0.373 |
|
| 2007 |
Rapoport AP, Grupp SA, Stadtmauer EA, Vonderheide RH, Levine BL, Fang H, Yager K, Chew A, Veloso E, June CH. Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant. Blood. 110: 769-769. DOI: 10.1182/Blood.V110.11.769.769 |
0.443 |
|
| 2006 |
Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, ... ... Vonderheide RH, et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5725-34. PMID 17179106 DOI: 10.1200/Jco.2005.05.3314 |
0.455 |
|
| 2006 |
Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, ... ... Vonderheide RH, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 1150-60. PMID 17085308 DOI: 10.1016/J.Bbmt.2006.06.015 |
0.412 |
|
| 2006 |
Sterman DH, Gillespie CT, Carroll RG, Coughlin CM, Lord EM, Sun J, Haas A, Recio A, Kaiser LR, Coukos G, June CH, Albelda SM, Vonderheide RH. Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nature Clinical Practice. Oncology. 3: 633-9. PMID 17080181 DOI: 10.1038/Ncponc0658 |
0.342 |
|
| 2006 |
Clark CE, Vonderheide RH. Cancer-testis antigens in tumor biology and immunotherapy. Cancer Biology & Therapy. 5: 1226-7. PMID 17021387 DOI: 10.4161/Cbt.5.9.3343 |
0.402 |
|
| 2006 |
Carpenter EL, Vonderheide RH. Telomerase-based immunotherapy of cancer. Expert Opinion On Biological Therapy. 6: 1031-9. PMID 16989585 DOI: 10.1517/14712598.6.10.1031 |
0.646 |
|
| 2006 |
Lendvai N, Gnjatic S, Ritter E, Chen Y, Coughlin C, Vonderheide RH, Niesvizky R, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. Host Immune Responses Against CT Antigens in Multiple Myeloma Patients. Blood. 108: 3492-3492. DOI: 10.1182/Blood.V108.11.3492.3492 |
0.383 |
|
| 2006 |
Albelda SM, Haas A, Gillespie C, Recio A, Sun J, Kapoor V, Brown J, Michael P, Ho M, Pastan I, Vonderheide RH, Carroll R, June C, Kaiser LR, Sterman DH. 1108. High Rate of Anti-Tumor Immune Responses in a Phase 1 Clinical Trial of Adenoviral-Interferon-Beta Gene Transfer for Malignant Mesothelioma (MM) and Malignant Pleural Effusions (MPE) Molecular Therapy. 13: S426. DOI: 10.1016/J.Ymthe.2006.08.1213 |
0.359 |
|
| 2006 |
Sterman DH, Recio A, Haas A, Machuzak M, Gillespie C, Sun J, Kapoor V, Litzky LA, Vonderheide R, June C, Kucharczuk JC, Kaiser LR, Albelda SM. 1106. Results of a Phase I Clinical Trial of Adenoviral-Interferon-Beta Gene Therapy for Malignant Mesothelioma and Malignant Pleural Effusions Molecular Therapy. 13: S425. DOI: 10.1016/J.Ymthe.2006.08.1211 |
0.326 |
|
| 2006 |
Hardy N, Fellowes V, Mariotti J, Carter C, June C, Levine B, Hakim F, Vonderheide R, Gress R, Read E, Fowler D, Bishop M. Adoptive immunotherapy with tumor-derived donor lymphocytes after allogeneic hematopoietic stem cell transplantation Biology of Blood and Marrow Transplantation. 12: 44. DOI: 10.1016/J.Bbmt.2005.11.139 |
0.39 |
|
| 2005 |
Domchek SM, Fox KR, Recio A, Schuchter LM, Davidson R, Demichele A, Feldman MD, Vonderheide RH. Telomerase vaccination of metastatic breast cancer patients induces antigen-specific tumor infiltrating lymphocytes and tumor necrosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2505. PMID 27945956 DOI: 10.1200/Jco.2005.23.16_Suppl.2505 |
0.531 |
|
| 2005 |
Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domchek SM, Vonderheide RH. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Experimental Hematology. 33: 1275-80. PMID 16263411 DOI: 10.1016/J.Exphem.2005.07.011 |
0.448 |
|
| 2005 |
Clark CE, Vonderheide RH. Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5333-6. PMID 16061844 DOI: 10.1158/1078-0432.Ccr-05-1057 |
0.496 |
|
| 2005 |
Maecker B, Von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Anderson KC, Nadler LM, Schultze JL. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients Clinical and Experimental Immunology. 141: 558-562. PMID 16045747 DOI: 10.1111/J.1365-2249.2005.02879.X |
0.444 |
|
| 2005 |
DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM, Vonderheide RH. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biology & Therapy. 4: 342-6. PMID 15846066 DOI: 10.4161/Cbt.4.3.1644 |
0.484 |
|
| 2005 |
Snyder K, Zhang H, Vance B, June CH, Vonderheide R, Mackall C. Evaluation of the CD8+ Tumor Associated vs. Non-Tumor Associated Immune Repertoire in Cancer Patients Following Induction of Lymphopenia and Following CD3/4-1BB Based Expansion. Blood. 106: 2390-2390. DOI: 10.1182/Blood.V106.11.2390.2390 |
0.476 |
|
| 2004 |
Patel KP, Vonderheide RH. Telomerase as a tumor-associated antigen for cancer immunotherapy. Cytotechnology. 45: 91-9. PMID 19003246 DOI: 10.1007/S10616-004-5132-2 |
0.549 |
|
| 2004 |
Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 828-39. PMID 14871958 DOI: 10.1158/1078-0432.Ccr-0620-3 |
0.519 |
|
| 2004 |
Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. The Journal of Clinical Investigation. 113: 425-33. PMID 14755339 DOI: 10.1172/Jci19418 |
0.395 |
|
| 2004 |
Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood. 103: 2046-54. PMID 14630810 DOI: 10.1182/Blood-2003-07-2379 |
0.473 |
|
| 2004 |
Overley B, Coughlin CM, Leibowitz MS, Sorenmo KU, Vonderheide RH. RNA-transfected CD40-activated B cells as a vaccine strategy in canine malignancies Veterinary and Comparative Oncology. 2: 103-103. DOI: 10.1111/J.1476-5810.2004.0045H.X |
0.462 |
|
| 2003 |
Coughlin CM, Vonderheide RH. Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modality. Cancer Biology & Therapy. 2: 466-70. PMID 14614310 DOI: 10.4161/Cbt.2.5.445 |
0.47 |
|
| 2003 |
Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 102: 3287-94. PMID 12869499 DOI: 10.1182/Blood-2003-05-1374 |
0.515 |
|
| 2003 |
Vonderheide RH, June CH. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunologic Research. 27: 341-56. PMID 12857980 DOI: 10.1385/Ir:27:2-3:341 |
0.54 |
|
| 2003 |
Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. British Journal of Haematology. 121: 842-8. PMID 12786794 DOI: 10.1046/J.1365-2141.2003.04375.X |
0.478 |
|
| 2003 |
Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 102: 2004-13. PMID 12763934 DOI: 10.1182/Blood-2003-01-0095 |
0.441 |
|
| 2003 |
Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America. 100: 3398-403. PMID 12626761 DOI: 10.1073/Pnas.0530311100 |
0.537 |
|
| 2002 |
Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy Cytotherapy. 4: 317-327. PMID 12396831 DOI: 10.1080/146532402760271091 |
0.51 |
|
| 2002 |
Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 168: 5900-6. PMID 12023395 DOI: 10.4049/Jimmunol.168.11.5900 |
0.446 |
|
| 2002 |
von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 99: 3319-25. PMID 11964299 DOI: 10.1182/Blood.V99.9.3319 |
0.488 |
|
| 2002 |
Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 21: 674-9. PMID 11850795 DOI: 10.1038/Sj.Onc.1205074 |
0.483 |
|
| 2001 |
Maecker B, Von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Schultze JL. Linking genomics to immunotherapy by reverse immunology mmmunomics' in the New Millennium Current Molecular Medicine. 1: 609-619. PMID 11899235 DOI: 10.2174/1566524013363447 |
0.364 |
|
| 2001 |
Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Research. 61: 8366-70. PMID 11731409 |
0.466 |
|
| 2001 |
Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase Clinical Cancer Research. 7: 3343-3348. PMID 11705846 |
0.33 |
|
| 2001 |
Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL, Nadler LM. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity International Journal of Oncology. 19: 791-798. PMID 11562757 DOI: 10.3892/Ijo.19.4.791 |
0.428 |
|
| 2001 |
Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: Toward second-generation tumor antigens Trends in Immunology. 22: 516-523. PMID 11525943 DOI: 10.1016/S1471-4906(01)02015-4 |
0.487 |
|
| 2001 |
Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG. Phase I study of recombinant human CD40 ligand in cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3280-7. PMID 11432896 DOI: 10.1200/Jco.2001.19.13.3280 |
0.408 |
|
| 2001 |
Schultze JL, Maecker B, Von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH. Tumour immunotherapy: New tools, new treatment modalities and new T-cell antigens Vox Sanguinis. 80: 81-89. PMID 11378969 DOI: 10.1046/J.1423-0410.2001.00014.X |
0.456 |
|
| 2000 |
Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, Gribben JG. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies Nature Medicine. 6: 667-672. PMID 10835683 DOI: 10.1038/76243 |
0.494 |
|
| 2000 |
Andersen KS, Wucherpfennig KA, Nicholas Haining W, Schultze JL, Maecker B, Xia Z, Butler MO, Vonderheide RH, Nadler LM. Potential of antigen-specific adoptive immunotherapy using peptide/mhc tetramers and microbeads for highyield purification of cytotoxic t lymphocytes from peripheral blood Blood. 96. |
0.382 |
|
| 1999 |
Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes Immunity. 10: 673-679. PMID 10403642 DOI: 10.1016/S1074-7613(00)80066-7 |
0.504 |
|
| 1992 |
Vonderheide RH, Springer TA. Lymphocyte adhesion through very late antigen 4: Evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional α4 integrin counter-receptor on stimulated endothelium Journal of Experimental Medicine. 175: 1433-1442. PMID 1375259 DOI: 10.1084/Jem.175.6.1433 |
0.335 |
|
| 1991 |
Vonderheide RH, Hunt SV. Comparison of lgD+ and lgD- thoracic duct B lymphocytes as germinal center precursor cells in the rat International Immunology. 3: 1273-1281. PMID 1777422 DOI: 10.1093/Intimm/3.12.1273 |
0.771 |
|
| 1990 |
Vonderheide RH, Hunt SV. Immigration of thoracic duct B lymphocytes into established germinal centers in the rat European Journal of Immunology. 20: 79-86. PMID 2307178 DOI: 10.1002/Eji.1830200112 |
0.771 |
|
| 1990 |
Vonderheide RH, Hunt SV. T lymphocytes in rat germinal centres belong to an ER3+ subpopulation of CD4+ cells Immunology. 69: 542-547. PMID 1970805 |
0.309 |
|
| 1990 |
Vonderheide RH, Hunt SV. Does the availability of either B cells or CD4+ cells limit germinal centre formation? Immunology. 69: 487-489. PMID 1968890 |
0.332 |
|
| 1988 |
Vonderheide RH, Hunt SV. Surface IgD phenotype of rat germinal centre precursor cells Advances in Experimental Medicine and Biology. 237: 239-243. PMID 3267049 DOI: 10.1007/978-1-4684-5535-9_36 |
0.766 |
|
| Show low-probability matches. |